The insurance route, explained properly
The FAQ sets out what a prior authorisation is, that the insurer decides it and not the seller, that the copay depends on the plan, and that the authorisation lapses if the membership does. That is four things most sellers on this roster leave a reader to discover.
The copay figure it advertises is not a cash price and cannot be differenced against one. We have recorded it in the field for coverage-conditioned figures rather than in the price rows; five of the one hundred and fifty-eight sellers here carry a figure that holds only once coverage is in place.
The same page states the underlying cash figure the copay reduces, which is what makes the claim checkable rather than decorative.
Two compounded price sets in one document
The FAQ quotes compounded semaglutide as low as one figure when a three-month supply is bought, and separately prices a semaglutide bundle at a first month followed by a standing rate nearly double that figure. Tirzepatide gets the same treatment, with the two standing rates differing by more than double.
Nothing in the document reconciles them. They are not a promotional rate and a renewal rate; both are described as ongoing, in different answers to different questions.
All four rows are recorded, each against the phrasing that produced it. A reader should ask which one applies to them before treating either as the price.
The warning letter, and the entity behind it
The operating entity received an FDA warning letter in June 2026. It is disclosed here with its number, its date and a link to the agency's text, and it does not move this row's position or score.
The letter was found by querying the operating company rather than the brand. That query returned three letters across three different trading names of the same company, one of which is a separate seller already on this roster. A brand-keyed or domain-keyed search would have returned the wrong subset.
The privacy policy names a limited liability company doing business under the brand and, elsewhere on the same page, a corporation of the brand name, both at the same New York address. The membership is priced for a first month and never for any month after it.
AM Rx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $151/moas low as, and the FAQ conditions it on "purchasing a 3-month supply"; the same FAQ separately prices a Semaglutide Bundle at "$217 for your first month, then $297 per month", so the site carries two standing compounded semaglutide rates that differ by nearly double | September 2026source |
| Semaglutide (compounded) | $297/mothe renewal rate of the Semaglutide Bundle, printed as "$217 for your first month, then $297 per month" in the same FAQ that gives the $151 figure | September 2026source |
| Tirzepatide (compounded) | $216/moas low as, with shipping included, in the same passage as the $151 semaglutide figure | September 2026source |
| Tirzepatide (compounded) | $449/mothe renewal rate of the Tirzepatide Bundle, printed as "$349 for your first month, then $449 per month" - more than double the $216 the same document quotes for compounded tirzepatide | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See AM Rx's current price →Good fit if
- Readers weighing an insurance-coverage route against a cash compounded one.
- Buyers who want the prior-authorisation process explained before they start.
- People who will read a long FAQ closely enough to notice which price applies to them.
Look elsewhere if
- Readers who will not buy from a company with a recorded FDA warning letter.
- Anyone who wants one standing price per drug; this seller publishes two for each.
- Buyers who need to know what the membership costs after the first month.
- People who need the pharmacy named or a service area published.
How this review was verified
- Read the weight-loss page, the FAQ and the privacy policy on 6 September 2026, with a nonsense-path control on the host in the same run.
- Recorded the copay figure in the coverage-conditioned field rather than as a price, because the FAQ states it depends on an approved prior authorisation and an active membership.
- Recorded both compounded price sets, each against the phrasing that produced it, rather than choosing the lower one.
- Screened by the operating entity rather than the brand, which is what returned the letter; a brand query returned it too, buried in ten unrelated full-text matches.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable with a positive and a negative control in the same pass. The entity query returned a letter to FitRX, LLC dba AM RX, No. 728275, issued 8 June 2026; the letter page was then fetched directly and its recipient block matched the entity and the contact address published on the seller's own site. A minted, non-existent letter path on the same host returned a not-found status in the same run.